Ipsen S.A.
IPSEY News Today: Stay Updated with the Latest Ipsen S.A. News in Real Time
Find IPSEY news now at Meyka AI. Stay informed with the latest Ipsen S.A. stocks updates, including price news, market analysis, and expert insights.
IPSEY: Deutsche Bank Maintains Buy Rating, May 2026
Deutsche Bank maintains Buy rating on Ipsen (IPSEY), raising price target to EUR 183 from EUR 170 on May 14, 2026.
EXEL Earnings Beat: Exelixis Crushes EPS Estimate by 16%
Exelixis (EXEL) beat Q1 2026 EPS estimate by 16% at $0.87 vs $0.75 expected. Revenue hit $610.81M, up 0.54% from forecast.
IPSEY Maintained at Buy by Deutsche Bank, April 2026
Deutsche Bank maintained IPSEY at Buy with price target raised to EUR 183 from EUR 170 on April 14, 2026.
Deutsche Bank maintains Buy on IPSEY Ipsen S.A. Feb 17 2026
Deutsche Bank maintains Buy and raises PT to EUR 170 for IPSEY analyst rating on Feb 17, 2026
IPN.PA Ipsen S.A. (EURONEXT) up 11.46% on 13 Feb 2026: guidance lifts outlook
IPN.PA stock rises to €154.70 after strong 2025 results and bullish 2026 guidance; Meyka AI analysis and forecast included
Ipsen Stock Jumps 6% on Strong Q3 Results and Somatuline Boost
Ipsen S.A., the French biopharmaceutical company, saw its stock jump 6% on October 22, 2025, after releasing strong third-quarter results. The rally came as investors cheered solid sales growth and renewed momentum from its blockbuster drug Somatuline. Ipsen’s quarterly report showed not just higher revenues but also stronger margins and improving guidance for the rest…